[Elsevier] Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 “DICIPLE” Phase III Trial |
|
This post will be closed automatically in 2026-06-23 03:47
Reward10points
|
10
Wide-tunable LC-VCO design with a novel active inductor
10
Utilizing YOLOv8 for enhanced traffic monitoring in intelligent transportation systems (ITS) applications
10
Impact of tunnel lighting on driver perception and safety in foggy conditions
10
Evaluating the effects of brake light flicker frequency on cognitive conspicuity during visual dark adaptation: A 360-degree simulated driving study
10
Digital Twin-enabled and Knowledge-driven decision support for tunnel electromechanical equipment maintenance
